Tag: Crohn's disease
AbbVie to acquire Landos Biopharma to bolster autoimmune disease treatments
AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, Inc. (NASDAQ: LABP) have announced a landmark agreement, marking a strategic move in the biopharmaceutical sector focused on ... Read More
Eli Lilly’s mirikizumab triumphs in Phase 3 Crohn’s disease study
Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated its prowess against placebo in the critical ... Read More
Merck to acquire biotech company Prometheus Biosciences for $10.8bn
Merck has agreed to acquire Prometheus Biosciences, a Nasdaq-listed clinical-stage biotechnology company, in an all-cash deal worth around $10.8 billion, in a move to bolster ... Read More
Crohn’s disease diet plan | What foods should be avoided by Crohn’s patients
In this post let us know about Crohn's disease diet plan. What foods should be taken and what foods need to be avoided? Crohn's disease ... Read More
Crohn’s disease diagnosis and treatment
How is Crohn’s disease diagnosed? Crohn's disease cannot be identified by any single test. The physician will start identifying the condition by eliminating possible causes ... Read More
What is Crohn’s disease – symptoms and causes
What is Crohn's disease? How common is Crohn's disease? Crohn's disease is a form of inflammatory bowel disease (IBD). Crohn's disease typically occurs within the ... Read More
AzurRx BioPharma acquires US biotech company First Wave Bio for $229m
AzurRx BioPharma has signed a stock and cash deal worth $229 million to acquire Florida-based clinical-stage biotech company First Wave Bio. The consideration includes payments ... Read More
Amgen seeks FDA approval for infliximab biosimilar ABP 710
Amgen has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to Johnson & ... Read More
Hyrimoz EC approval : Novartis biosimilar of AbbVie Humira approved in EU
Hyrimoz EC approval : Novartis’ Sandoz has bagged approval for Hyrimoz (adalimumab), a biosimilar of AbbVie’s Humira (adalimumab), in Europe for all indications of the ... Read More